Skip to content
Schedule a demo
About the database
On this page:OverviewPublicationsResearchersInstitutionsOpen access
PICO Portalanswers from OpenAlex

Comprehensive Cancer Centers of Nevada

InstitutionResearch output, impact & collaborations

Comprehensive Cancer Centers of Nevada is a institution indexed in PICO Portal from OpenAlex.

What is known about Comprehensive Cancer Centers of Nevada?

PICO Portalrecord summary

Comprehensive Cancer Centers of Nevada is a research organisation in Las Vegas, US. OpenAlex records 1,231 works and 73,701 citations for it. 125 researchers list it as their most recent affiliation.

How many works does Comprehensive Cancer Centers of Nevada have?

PICO Portalindexed works

Comprehensive Cancer Centers of Nevada has 1,231 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Comprehensive Cancer Centers of Nevada have?

PICO Portalcitation count

Comprehensive Cancer Centers of Nevada has 73,701 citations in the OpenAlex counts PICO Portal stores.

How many researchers are at Comprehensive Cancer Centers of Nevada?

PICO Portalresearcher count

Comprehensive Cancer Centers of Nevada has 125 researchers in the PICO Portal index.

What is the average h-index at Comprehensive Cancer Centers of Nevada?

PICO Portalavg h-index

Comprehensive Cancer Centers of Nevada has an average h-index of 116 in OpenAlex.

What is the ROR of Comprehensive Cancer Centers of Nevada?

PICO Portalror

The ROR for Comprehensive Cancer Centers of Nevada is on the source record.

What is the OpenAlex record for Comprehensive Cancer Centers of Nevada?

PICO Portalopenalex

The OpenAlex for Comprehensive Cancer Centers of Nevada is on the source record.

Who are the most-cited researchers behind Comprehensive Cancer Centers of Nevada?

PICO Portaltop researchers by citations
1
Nicholas J. Vogelzang · Prostate Cancer Treatment and Research
1,125 works69,898 citations

What are the most-cited papers on Comprehensive Cancer Centers of Nevada?

PICO Portalmost cited works
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin
New England Journal of Medicine. 20173,424 CitationsOPEN ACCESS
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney, Yu‐Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard, Mario A. Eisenberger, Yu-Ning Wong, Noah M. Hahn, Manish Kohli, Matthew M. Cooney, Robert Dreicer, Nicholas J. Vogelzang, Joel Picus, Daniel H. Shevrin, Maha Hussain, Jorge A. García, Robert S. DiPaola
New England Journal of Medicine. 20152,869 CitationsOPEN ACCESS
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Christos E. Kyriakopoulos, Yu‐Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard, Noah M. Hahn, Daniel H. Shevrin, Robert Dreicer, Maha Hussain, Mario A. Eisenberger, Manish Kohli, Elizabeth R. Plimack, Nicholas J. Vogelzang, Joel Picus, Matthew M. Cooney, Jorge A. García, Robert S. DiPaola, Christopher J. Sweeney
Journal of Clinical Oncology. 20181,116 CitationsOPEN ACCESS
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
Maha Hussain, Catherine M. Tangen, Donna L. Berry, Celestia S. Higano, E. David Crawford, Glenn Liu, George Wilding, Stephen M. Prescott, S.K. Sundaram, Eric J. Small, Nancy A. Dawson, Bryan Donnelly, Peter Venner, Ulka N. Vaishampayan, Paul F. Schellhammer, David I. Quinn, Derek Raghavan, Benjamin Ely, Carol M. Moinpour, Nicholas J. Vogelzang, Ian M. Thompson
New England Journal of Medicine. 2013574 CitationsOPEN ACCESS
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook, Karl D. Lewis, Jeffrey R. Infante, Michael S. Gordon, Nicholas J. Vogelzang, Douglas J. DeMarini, Peng Sun, Christopher Moy, Stephen A. Szabo, Lori Roadcap, Vijay Peddareddigari, Peter F. Lebowitz, Ngocdiep T. Le, Howard A. Burris, Wells A. Messersmith, Peter J. O’Dwyer, Kevin B. Kim, Keith T. Flaherty, Johanna C. Bendell, René González, Razelle Kurzrock, Leslie A. Fecher
The Lancet Oncology. 2012545 CitationsOPEN ACCESS

How much of the research on Comprehensive Cancer Centers of Nevada is open access?

PICO Portalopen access share
100%OPEN ACCESS
Gold
0%
Green
50%
Hybrid
0%
Bronze
50%
Closed
0%

Related on PICO Portal

Prostate Cancer Treatment and Research
Top Topic
Cancer Immunotherapy and Biomarkers
Top Topic
Radiopharmaceutical Chemistry and Applications
Top Topic
Advanced Radiotherapy Techniques
Top Topic
Renal cell carcinoma treatment
Top Topic
Bladder and Urothelial Cancer Treatments
Top Topic
470M+ articles · 14-day free trial